Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly to $448 from $444 and keeps an Overweight rating on the shares after adjusting the firm’s models for recent IQVIA trends as well as intraquarter updates. Within the large cap pharma group, the firm sees a need to remain selective and believes that companies that can deliver growth in the second half of the decade are best positioned.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data
- TD Cowen pharmaceuticals analysts to hold analyst/industry conference call
- Eli Lilly price target raised to $310 from $290 at Jefferies
- Lilly reports Alzheimer’s treatment reduced amyloid in small study, Reuters says
- Viking Therapeutics price target raised to $31 from $20 at BTIG